Metoprolol XR in Heart Failure With Normal Ejection Fraction
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
In contrast to the treatment of HF with reduced EF, information to guide the pharmacological
therapy of patients with HFNEF are lacking and there is no evidence based treatment for
patients with HFNEF. Thus, present treatment strategies for HFNEF are largely based on
assumptions regarding its pathophysiological mechanisms and on extrapolations from proven
strategies used in systolic HF. Till now, no study enlightens the efficacy and safety of beta
blockers in HFNEF in a randomised controlled manner although the role of beta blockers in HF
with impaired systolic function has been sufficiently time tested leading to their
therapeutic approval in that condition. Keeping in view the small reported benefit of beta
blockers in HFNEF as mentioned above, there is a need to provide a conclusive proof of their
role in this condition as well. Hence, investigators planned to test the efficacy and safety
of metoprolol CR in patients with HFNEF in a randomised double blind placebo controlled
trial.
Phase:
Phase 2
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research